|
颈动脉支架置入术后循环血小板活化和聚集的系列变化 |
| |
nbsp;a more reliable marker of in vivo platelet activation than CD62P flow cytometric analysis［J］? Thromb Haemost,1999,81:472-473.
［11］ ANDRé P, NANNIZZI-ALAIMO L, PRASAD KS, et al. Platelet-derived CD 40L: the switch-hitting player of cardiovascular disease［J］. Circulation,2002,106:896-899.
［12］ ANDRé P, PRASAD KS, DENIS CV, et al. CD 40L stabilizes arterial thrombi by a beta-3 integrin–dependent mechanism［J］. Nat Med, 2002,8: 247–252.
［13］ WILLMOTT TG, SELKIRK CP, HAWKES RB, et al. PAC-1: an epitope associated with two novel glycoprotein components of isolated postsynaptic densities and a novel cytoskeleton- associated polypeptide［J］. Neuroscience, 1991, 44: 627 - 641.
［14］ MATZDORFF A. Platelet function tests and flow cytometry to monitor antiplatelet therapy［J］. Semin Thromb Hemost, 2005, 31:393-399.
［15］ GAWAZ M, NEUMANN FJ, OTT I, et al. Platelet activation and coronary stent implantation［J］. Circulation,1996,94:279-285.
［16］ FURMAN MI, KRUEGER LA, LINDEN MD, et al. GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention［J］. J Thromb Haemost,2005,3:312-320.
［17］ MICHELSON AD. F上一页 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 下一页
上一个医学论文： 丹参干预 型胶原诱导的类风湿性关节炎大鼠血清D 二聚体的变化
下一个医学论文： 冠心病合并慢性心力衰竭患者血管性血友病因子水平的变化
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文